Risks of using SSRI / SNRI antidepressants during pregnancy and lactation

Open access

Abstract

At present, affective disorders are among the most commonly diagnosed mental diseases. In pregnancy, they can occur as pre-delivery depression, recurrent depressive disorder or postnatal depression. The estimated prevalence of depressive disorders in pregnancy is approximately 9–16%, with some statistics reporting up to 20%. Approximately 2–3% of pregnant women take antidepressants during pregnancy, and the number of mothers treated increases by birth to 5–7%. Treatment of depression during pregnancy and breastfeeding is a controversial issue, as antidepressants can negatively affect the developing fetus. According to epidemiological studies, the effects of treated depression in pregnancy are related to premature birth, decreased body weight of the child, intrauterine growth retardation, neonatal adaptive syndrome, and persistent pulmonary hypertension. However, untreated depression can adversely affect maternal health and increase the risk of preeclampsia and eclampsia, as well as of subsequent postnatal depression, which can lead to disruption of the mother-child relationship. Based on the above mentioned facts, the basic question arises as to whether or not to treat depression during pregnancy and lactation.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Addis A Koren G. (2000). Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 30: 89–94.

  • Başterzi AD Yazici K Aslan E Delialioğlu N Taşdelen B Tot Acar S Yazici A. (2009). Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 33: 281–5.

  • Bruschettini M van den Hove DL Gazzolo D Bruschettini P Blanco CE Stein-busch HW. (2005). A single course of antenatal betamethasone reduces neurotrophic factor S100B concentration in the hippocampus and serum in the neonatal rat. Brain Res Dev Brain Res 159: 113–8.

  • Clarke C Clarke K Muneyyirci J Azmitia E Whitaker-Azmitia PM. (1996). Prenatal cocaine delays astroglial maturation: immunodensitometry shows increased markers of immaturity (vimentin and GAP-43) and decreased proliferation and production of the growth factor S-100. Brain Res Dev Brain Res 91: 268–73.

  • da-Silva VA Altenburg SP Malheiros LR Thomaz TG Lindsey CJ. (1999). Post-natal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. Brazilian J Med Biol Res 32: 93–8.

  • de Bruijn ATCE van Bakel HJA Wijnen H Pop VJM van Baar AL. (2009). Prenatal maternal emotional complaints are associated with cortisol responses in toddler and preschool aged girls. Dev Psychobiol 51: 553–63.

  • de Oliveira RA Cunha GMA Borges KDM de Bruin GS dos Santos-Filho EA Viana GSB de Bruin VMS. (2004). The effect of venlafaxine on behaviour body weight and striatal monoamine levels on sleep-deprived female rats. Pharmacol Biochem Behav 79: 499–506.

  • Dennis C-L. (2005). Psychosocial and psychological interventions for prevention of postnatal depression: systematic review. BMJ 331: 15–0.

  • Drevets WC Todd RD. (2005). Depression mania and related disorders. In: Rubin E Zorumski C (eds). Adult Psychiatry 2nd edn. Blackwell Oxford pp. 91–129.

  • Dubovický M Császárová E Brnoliaková Z Ujházy E Navarová J Mach M. (2012). Effect of prenatal administration of venlafaxine on postnatal development of rat offspring. Interdiscip Toxicol 5: 92–7.

  • Duman RS Malberg J Nakagawa S D‘Sa C. (2000). Neuronal plasticity and survival in mood disorders. Biol Psychiatry 48: 732–9.

  • Einarson A Choi J Einarson TR Koren G. (2009). Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 54: 242–6.

  • Galbally M Lewis AJ Lum J Buist A. (2009). Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry 43(9): 846–54.

  • Gazzolo D Kornacka M Bruschettini M Lituania M Giovannini L Serra G Majewska U Michetti F. (2003). Maternal glucocorticoid supplementation and S100B protein concentrations in cord blood and urine of preterm infants. Clin Chem 49: 1215–8.

  • Gausia K Fisher C Ali M Oosthuizen J. (2009). Antenatal depression and suicidal ideation among rural Bangladeshi women: a community-based study. Arch Womens Ment Health 12: 351–358.

  • Gentile S. (2005). The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 28: 137–52.

  • Gentile S. (2011). Suicidal mothers. J Inj Violence Res 3: 90–7.

  • Gerardin P Wendland J Bodeau N Galin A Bialobos S Tordjman S Mazet P Darbois Y Nizard J Dommergues M Cohen D. (2011). Depression during pregnancy: is the developmental impact earlier in boys? A prospective case-control study. J Clin Psychiatry 72: 378–87.

  • Grote V Vik T von Kries R Luque V Socha J Verduci E Carlier C Koletzko B. (2010). Maternal postnatal depression and child growth: a European cohort study. BMC Pediatr 10: 14.

  • Gump BB Reihman J Stewart P Lonky E Darvill T Granger DA Matthews KA. (2009). Trajectories of maternal depressive symptoms over her child’s life span: relation to adrenocortical cardiovascular and emotional functioning in children. Dev Psychopathol 21: 207–25.

  • Harmer CJ Cowen PJ. (2013). “It”s the way that you look at it’--a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc B Biol Sci 368: 20120407–20120407.

  • Hartley M Tomlinson M Greco E Comulada WS Stewart J le Roux I Mbewu N Rotheram-Borus MJ. (2011). Depressed mood in pregnancy: prevalence and correlates in two Cape Town peri-urban settlements. Reprod Health 8: 9.

  • Herlenius E Lagercrantz H. (2004). Development of neurotransmitter systems during critical periods. Exp Neurol 190 Suppl: S8–21.

  • Hesketh J Baudier J. (1986). Evidence that S100 proteins regulate microtubule assembly and stability in rat brain extracts. Int J Biochem 8: 691–5.

  • Hollins K. (2007). Consequences of antenatal mental health problems for child health and development. Curr Opin Obstet Gynecol 19: 568–72.

  • Chen B Dowlatshahi D MacQueen GM Wang JF Young LT. (2001). Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 50: 260–5.

  • Karmaliani R Asad N Bann CM Moss N Mcclure EM Pasha O Wright LL Goldenberg RL. (2009). Prevalence of Anxiety Depression and Associated Factors Among Pregnant Women of Hyderabad Pakistan. Int J Soc Psychiatry 55: 414–424.

  • Källén B Olausson PO. (2008). Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf 17: 801–6.

  • KINSELLA MT MONK C. (2009). Impact of Maternal Stress Depression and Anxiety on Fetal Neurobehavioral Development. Clin Obstet Gynecol 52: 425–440.

  • Leung BMY Kaplan BJ. (2009). Perinatal depression: prevalence risks and the nutrition link--a review of the literature. J Am Diet Assoc 109: 1566–75.

  • McDonald S Wall J Forbes K Kingston D Kehler H Vekved M Tough S. (2012). Development of a prenatal psychosocial screening tool for post-partum depression and anxiety. Paediatr Perinat Epidemiol 26: 316–27.

  • Mohammad KI Gamble J Creedy DK. (2011). Prevalence and factors associated with the development of antenatal and postnatal depression among Jordanian women. Midwifery 27: e238–e245.

  • Muzik M Hamilton SE. (2016). Use of Antidepressants During Pregnancy?: What to Consider when Weighing Treatment with Antidepressants Against Untreated Depression. Matern Child Health J 20: 2268–2279.

  • Nulman I Rovet J Stewart DE Wolpin J Pace-Asciak P Shuhaiber S Koren G. (2002). Child Development Following Exposure to Tricyclic Antidepressants or Fluoxetine Throughout Fetal Life: A Prospective Controlled Study. Am J Psychiatry 159: 1889–1895.

  • Oberlander TF. (2012). Fetal serotonin signaling: setting pathways for early childhood development and behavior. J Adolesc Health 51: S9–16.

  • Oberlander TF Bonaguro RJ Misri S Papsdorf M Ross CJD Simpson EM. (2008). Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 13: 65–73.

  • Oyebode F Rastogi A Berrisford G Coccia F. (2012). Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther 135: 71–7.

  • Pawluski JL Brummelte S Barha CK Crozier TM Galea LAM. (2009). Effects of steroid hormones on neurogenesis in the hippocampus of the adult female rodent during the estrous cycle pregnancy lactation and aging. Front Neuroendocrinol 30: 343–357.

  • Pittenger C Duman RS. (2008). Stress depression and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33: 88–109.

  • Popoli M Gennarelli M Racagni G. (2002). Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disord 4: 166–82.

  • Rayen I Steinbusch HWM Charlier TD Pawluski JL. (2013). Developmental fluoxetine exposure and prenatal stress alter sexual differentiation of the brain and reproductive behavior in male rat offspring. Psychoneuroendocrinology 38: 1618–29.

  • Rayen I van den Hove DL Prickaerts J Steinbusch HW Pawluski JL. (2011). Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. PLoS One 6: e24003.

  • Reis M Källén B. (2010). Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 40: 1723–33.

  • Rothermundt M Peters M Prehn JH Arolt V. (2003). S100B in brain damage and neurodegeneration. Microsc Res Tech 60: 614–32.

  • Sanz EJ De-las-Cuevas C Kiuru A Bate A Edwards R. (2005). Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet (London England) 365: 482–7.

  • Sheu FS Azmitia EC Marshak DR Parker PJ Routtenberg A. (1994). Glial-derived S100b protein selectively inhibits recombinant beta protein kinase C (PKC) phosphorylation of neuron-specific protein F1/GAP43. Brain Res Mol Brain Res 21: 62–6.

  • Shuey DL Sadler TW Lauder JM. (1992). Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors. Teratology 46: 367–78.

  • Talge NM Neal C Glover V. Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? J Child Psychol Psychiatry 48: 245–61.

  • Thormahlen GM. (2006). Paroxetine use during pregnancy: is it safe? Ann Pharmacother 40: 1834–7.

  • Van den Bergh BRH Mulder EJH Mennes M Glover V. (2005). Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A review. Neurosci Biobehav Rev 29: 237–58.

  • Whitaker-Azmitia PM. (1991). Role of serotonin and other neurotransmitter receptors in brain development: basis for developmental pharmacology. Pharmacol Rev 43(4): 553–61.

  • Witt WP Litzelman K Cheng ER Wakeel F Barker ES. (2014). Measuring stress before and during pregnancy: a review of population-based studies of obstetric outcomes. Matern Child Health J 18: 52–63.

  • Yonkers KA Wisner KL Stewart DE Oberlander TF Dell DL Stotland N Ramin S Chaudron L Lockwood C. (2009). The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 31: 403–413.

Search
Journal information
Impact Factor


CiteScore 2018: 1.78

SCImago Journal Rank (SJR) 2018: 0.274
Source Normalized Impact per Paper (SNIP) 2018: 0.671

Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 851 555 22
PDF Downloads 424 279 13